PLUS1
64.06
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| IGM Biosciences Inc | IGMS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 64.06 | 0.00 | 0.00 | 0.00 | 64.06 | 07:00:13 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 52.80 | 66.50 | 13.70 | 20.6% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 64.06 | USD |
IGM Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.96B | 30.59M | 30.08M | $ - | $ - | 7.12 | 8.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 16.00 | 1.70% |
IGM Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/28/2020 | 07:00 | GlobeNewswire Inc. | IGM Biosciences to Present at the Jefferies 2020 Healthcare.. |
| 5/12/2020 | 07:00 | GlobeNewswire Inc. | IGM Biosciences to Present at the 2020 RBC Capital Markets.. |
| 5/07/2020 | 16:32 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 16:03 | GlobeNewswire Inc. | IGM Biosciences Announces First Quarter 2020 Financial.. |
| 5/07/2020 | 16:02 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 4/29/2020 | 16:05 | GlobeNewswire Inc. | Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on.. |
| 4/21/2020 | 17:26 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IGMS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 59.98 | 68.00 | 59.00 | 63.95 | 115,749 | 4.08 | 6.8% |
| 1 Month | 54.98 | 68.00 | 51.45 | 59.72 | 83,261 | 9.08 | 16.52% |
| 3 Months | 52.75 | 70.00 | 27.55 | 52.74 | 90,076 | 11.31 | 21.44% |
| 6 Months | 23.00 | 74.13 | 19.605 | 44.92 | 129,331 | 41.06 | 178.52% |
| 1 Year | 18.31 | 74.13 | 16.10 | 38.24 | 127,699 | 45.75 | 249.86% |
| 3 Years | 18.31 | 74.13 | 16.10 | 38.24 | 127,699 | 45.75 | 249.86% |
| 5 Years | 18.31 | 74.13 | 16.10 | 38.24 | 127,699 | 45.75 | 249.86% |
IGM Biosciences Description
| IGM Biosciences Inc is a biotechnology company involved in the development of engineered IgM antibodies for the treatment of cancer patients. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. |
